Provided by Tiger Fintech (Singapore) Pte. Ltd.

Heron Therapeutics

1.97
+0.03501.81%
Volume:345.92K
Turnover:671.34K
Market Cap:299.79M
PE:-35.02
High:1.98
Open:1.94
Low:1.90
Close:1.93
Loading ...

HC Wainwright Initiates Coverage on Heron Therapeutics With Buy Rating, $6 Price Target

MT Newswires Live
·
09 Jun

Heron Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
09 Jun

Sector Update: Health Care Stocks Fall Late Afternoon

MT Newswires Live
·
07 May

Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise

MT Newswires Live
·
06 May

Heron Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate

Benzinga
·
06 May

Heron Therapeutics Settles Patent Dispute with Mylan

TIPRANKS
·
06 May

Heron Therapeutics Q1 EPS USD 0.01

THOMSON REUTERS
·
06 May

Heron Therapeutics: Adjusted Ebitda Guidance Raised to a Range of $4 Mln - $12 Mln for FY 2025

THOMSON REUTERS
·
06 May

BRIEF-Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations

Reuters
·
06 May

Heron Therapeutics: Grants Mylan License to Market Generic Cinvanti and Aponvie Beginning June 2032

THOMSON REUTERS
·
06 May

Heron Therapeutics Announces Settlement With Mylan Related to Cinvanti® and Aponvie® Patent Litigations

THOMSON REUTERS
·
06 May

Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
02 May

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks
·
29 Apr

Heron Therapeutics Appoints Mark Hensley as COO

TIPRANKS
·
29 Apr

Heron Therapeutics Names Mark Hensley as COO

MT Newswires Live
·
29 Apr

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

THOMSON REUTERS
·
29 Apr

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

PR Newswire
·
29 Apr

Heron Therapeutics Price Target Maintained With a $4.00/Share by Needham

Dow Jones
·
11 Apr

Exploring High Growth Tech Stocks In The US Market April 2025

Simply Wall St.
·
05 Apr